Inclusion criteria 1. Informed consent 2. Age ≥ 18 years 3. Confirmed septic shock: a. Confirmed or suspected infection b. Acute increase of ≥ 2 points on SOFA Score c. Need for continuous vasopressor therapy to maintain a mean arterial pressure (MAP) of > 65 mmHg despite adequate fluid resuscitation d. Blood lactate > 2 mmol/L (18 mg/dL)a 4. Tachycardia and/or tachyarrhythmia with heart rate ≥ 95 bpm 5. Norepinephrine infusion rate ≥ 0.2 μg/kg/min at the time of study inclusion 6. Patients must have undergone a hemodynamic optimization period of at least 24 h but a maximum of 36 h, during which period they received continuous vasopressor treatment and standard treatment for septic shock according to the SSCG 2016 guidelines aPresence of blood lactate > 2 mmol/L (18 mg/dL) and increase of ≥ 2 points on SOFA score are mandatory for the diagnosis of septic shock, but must not necessarily be present at the time of study inclusion Exclusion criteria: 1. Any form of compensatory tachycardia 2. β-blocker treatment within 72 h before randomization 3. Sick sinus syndrome, or second or third degree AV block 4. Patients with any form of cardiac pacing 5. A known serious cardiovascular condition such as ischemic stroke or transient ischemic attack within the last six months, or pre-existing heart failure NYHA class III or IV 6. Cardiogenic shock 7. MAP < 65 mmHg 8. Known pulmonary hypertension 9. Known terminal illness other than septic shock with expected patient’s survival < 28 days 10. Known presence of an advanced condition to withhold life-sustaining treatment 11. Patients for whom a “Do Not Resuscitate” (DNR) order exists 12. Known sensitivity to any component of the study medication (e.g. landiolol, mannitol) 13. Participation in a clinical drug trial within 30 days before randomization 14. Any condition that, in the investigator’s opinion, makes the individual unsuitable for study participation (to be documented) 15. Pregnant or breast-feeding patients 16. Untreated pheochromocytoma |